Fresh analysis indicates that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional diet and exercise programs.
Published data in a major health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users using these medications must be aware of the risk of fast rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to original mass in about a year and a half.
Weighing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Researchers note that individuals who shed pounds through diet and exercise generally have a more gradual creep back—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts suggest the mechanism of the drugs explains the heightened regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal could lead to the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means appetite is unsuppressed, making excessive eating far more likely."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, given the high risk of weight regain, the treatment should be considered long-term.
This perspective is supported by pharmaceutical companies, who say that the findings "highlight the long-term nature of excess weight," comparing it to managing diseases like hypertension.
User Testimonies
Individuals who have discontinued the medication explain a powerful return of appetite.
"It felt as if a switch flipping and you become starving," described an individual.
This difficulty is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among women compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and lasting health benefits hinges on integrated behavioural changes.
